MAY 26·SEC EDGARMed
SCULLY WILLIAM P purchased $981K of PRTA
SCULLY WILLIAM P purchased 100,000 shares of PROTHENA CORP PUBLIC LTD CO (PRTA) at $9.81 ($0.98M total) on 2026-05-22.
StockHealthcare · Biotechnology
$PRTA
PROTHENA CORP PUBLIC LTD CO
Price · $PRTAvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 1
- Neutral
- 0
- Bearish
- 0
Top stories · $PRTAMore →
APR 15·AD HOC NEWS
Prothena Corp plc stock (IE00B91XRN20): Why does its biotech pipeline matter more now for investors?
Prothena Corp plc is a clinical-stage biotechnology company focusing on therapies for neurodegeneration and amyloidosis, targeting diseases like Alzheimer's and AL amyloidosis. The company's pipeline, including lead candidate birtamimab and partner asset prasinezumab, leverages proprietary technologies to address significant unmet medical needs. With a strategic emphasis on partnerships and a lean operating model, Prothena aims to deliver high returns to investors through potential blockbuster drug approvals, especially for its Nasdaq-listed ADR (PRTA).
FEB 20·Business Wire
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
Prothena Corporation plc reported its financial results for the fourth quarter and full year 2025, detailing a net loss of $21.6 million and $244.1 million, respectively, and providing a financial guidance for 2026. The company highlighted advancements in its pipeline, including the initiation of Phase 3 clinical trials for prasinezumab and coramitug by its partners Roche and Novo Nordisk, respectively, and the progression of other partnered and proprietary programs. Prothena also discussed its cash position, expected net cash use for 2026, and the potential for a share redemption program.